High-density lipoprotein modulation targets

Drugs of the Future

Volumn 35, Issue 1, 2010, Pages 33-39

  Mousa, S S ^a   Block, R C ^b   Mousa, S A ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; ANACETRAPIB; ATORVASTATIN; BAY 60 5521; BEZAFIBRATE; CETI 1; CETI 1 VACCINE; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DALCETRAPIB; DRL 17822; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; JTT 302; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; PLACEBO; PRAVASTATIN; SIMVASTATIN; TA 8995; TORCETRAPIB; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; VACCINE;

ADD ON THERAPY; ALDOSTERONE BLOOD LEVEL; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; DIARRHEA; DIET; DRUG TARGETING; ELECTROLYTE BLOOD LEVEL; EXERCISE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INFLAMMATION; MORTALITY; NONHUMAN; NUTRITIONAL STATUS; REVIEW; SIDE EFFECT;

EID: 84930541232     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2010.035.01.1452012     Document Type: Review

References (49)

1. Kontush, A., Chapman, M.J. Functionally defective high-density lipoprotein: A new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 2006, 58(3): 342-374
2. Atzmon, G., Rincon, M., Rabizadeh, P. et al. Biological evidence for inheritance of exceptional longevity. Mech Ageing Dev 2005, 126(2): 341-345
3. Koropatnick, T.A., Kimbell, J., Chen, R. et al. A prospective study of high-density lipoprotein cholesterol, cholesteryl ester transfer protein gene variants, and healthy aging in very old Japanese-American men. J Gerontol A Biol Sci Med Sci 2008, 63(11): 1235-1240
4. Mueller, O., Chang, E., Deng, D. et al. PROCAM Study: Risk prediction for myocardial infarction using microfluidic high-density lipoprotein (HDL) subfractionation is independent of HDL cholesterol. Clin Chem Lab Med 2008, 46(4): 490-498
5. Atzmon, G. Plasma HDL levels highly correlate with cognitive function in exceptional longevity. J Gerontol A Biol Sci Med Sci 2002, 57: M712-5.
6. Arai, Y., Hirose, N. Aging and HDL metabolism in elderly people more than 100 years old. J Atheroscler Thromb 2004, 11(5): 246-252
7. Arai, Y., Hirose, N., Nakazawa, S. et al. Lipoprotein metabolism in Japanese centenarians - Effects of apolipoprotein E polymorphism and nutritional status. J Am Geriatr Soc 2001, 49(11): 1434-1441
8. Zhong, S., Sharp, D.S., Grove, J.S., Bruce, C., Yano, K., Curb, J.D., Tall, A.R. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 1996, 97(12): 2917-2923
9. Harris, T.B., Ferrucci, L., Tracy, R.P. et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999, 106(5): 506-512
10. Ross, R. Atherosclerosis - An inflammatory disease. N Engl J Med 1999, 340(2): 115-126
11. Kalantar-Zadeh, K., Kopple, J.D., Kamranpour, N., Fogelman, A.M., Navab, M. HDL-inflammatory index correlates with poor outcome in hemodialysis patients. Kidney Int 2007, 72(9): 1149-1156
12. Feng, H., Li, X.A. Dysfunctional high-density lipoprotein. Curr Opin Endocrinol Diabetes Obes 2009, 16(2): 156-162
13. Navab, M., Reddy, S.T., Van Lenten, B.J., Anantharamaiah, G.M., Fogelman, A.M. The role of dysfunctional HDL in atherosclerosis. J Lipid Res 2009, 50(Suppl.): S145-9.
14. Ferrieres, J. Effects on coronary atherosclerosis by targeting low-density lipoprotein cholesterol with statins. Am J Cardiovasc Drugs 2009, 9(2): 109-115
15. Duffy, D., Rader, D.J. Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport. Circulation 2006, 113(8): 1140-1150
16. Wang, N., Tall, A.R. Regulation and mechanisms of ATP-binding cassette transporter A1-mediated cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 2003, 23(7): 1178-1184
17. Barter, P. Metabolic abnormalities: High-density lipoproteins. Endocrinol Metab Clin North Am 2004, 33(2): 393-403.
18. Barter, P. The role of HDL-cholesterol in preventing atherosclerotic disease. Eur Heart J Suppl 2005, 7: F4-8.
19. Barter, P.J., Kastelein, J.J. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease. J Am Coll Cardiol 2006, 47(3): 492-499
20. DeSantis, P., Coleman, T., Schiekofer, S., Nawroth, P., Schlimmer, P., Schneider, J. Endothelial lipase: A key player in HDL metabolism modulates inflammation and atherosclerotic risk. Mini Rev Med Chem 2008, 8(6): 619-627
21. Barter, P.J., Nicholls, S., Rye, K.A., Anantharamaiah, G.M., Navab, M., Fogelman, A.M. Antiinflammatory properties of HDL. Circ Res 2004, 95(8): 764-772
22. Spanakis, E., Sidiropoulos, P., Papadakis, J. et al. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheumatol 2006, 33(12): 2440-2446
23. Silva, A.R., Pacheco, P., Vieira-de-Abreu, A. et al. Lipid bodies in oxidized LDL-induced foam cells are leukotriene-synthesizing organelles: A MCP-1/CCL2 regulated phenomenon. Biochim Biophys Acta 2009, 1791(11): 1066-1075
24. Robbesyn, F., Garcia, V., Auge, N. et al. HDL counterbalance the proinflammatory effect of oxidized LDL by inhibiting intracellular reactive oxygen species rise, proteasome activation, and subsequent NF-kappaB activation in smooth muscle cells. FASEB J 2003, 17(6): 743-745
25. Williams, P.T. Relationship of distance run per week to coronary heart disease risk factors in 8283 male runners. The National Runners' Health Study. Arch Intern Med 1997, 157(2): 191-198
26. Durstine, J.L., Grandjean, P.W., Davis, P.G., Ferguson, M.A., Alderson, N.L., DuBose, K.D. Blood lipid and lipoprotein adaptations to exercise: A quantitative analysis. Sports Med 2001, 31(15): 1033-1062
27. Williams, P.T. High-density lipoprotein cholesterol and other risk factors for coronary heart disease in female runners. N Engl J Med 1996, 334(20): 1298-1303
28. Lippi, G., Schena, F., Salvagno, G., Montagnana, M., Ballestrieri, F., Guidi, G. Comparison of the lipid profile and lipoprotein(a) between sedentary and highly trained subjects. Clin Chem Lab Med 2006, 44(3): 322-326
29. Lichtenstein, A.H. Dietary fat and cardiovascular disease risk: Quantity or quality? J Womens Health 2003, 12(2): 109-114
30. Rosenson, R.S. Antiatherothrombotic effects of nicotinic acid. Atherosclerosis 2003, 171(1): 87-96.
31. van der Hoorn, J.W., de Haan, W., Berbee, J.F., Havekes, L.M., Jukema, J.W., Rensen, P.C., Princen, H.-M. Niacin increases HPL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice. Arterioscler Thromb Vasc Biol 2008, 28(11): 2016-2022
32. Bays, H. Review of ARBITER 2: Extended-release niacin added to statin therapy slows the progression of atherosclerosis. Commentary. Postgrad Med 2009, 121(2): 195-198
33. Miyauchi, K., Takaya, N., Hirose, T. et al. Rationale and design of the carotid plaque in human for all evaluations with aggressive rosuvastatin therapy (CHALLENGER trial): Evaluation by magnetic resonance imaging. Circ J 2009, 73(1): 111-115
34. Taylor, A.J., Sullenberger, L.E., Lee, H.J., Lee, J.K., Grace, K.A. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004, 110(23): 3512-3517
35. de Haan, W., van der Hoogt, C.C., Westerterp, M. et al. Atorvastatin Increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice. Atherosclerosis 2008, 197(1): 57-63.
36. van der Hoogt, C.C., de Haan, W., Westerterp, M. et al. Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression. J Lipid Res 2007, 48(8): 1763-1771
37. Kontush, A., Guerin, M., Chapman, M.J. Spotlight on HDL-raising therapies: Insights from the torcetrapib trials. Nat Clin Pract Cardiovasc Med 2008, 5(6): 329-336 (Pubitemid 351761707)
38. Vergeer, M., Bots, M.L., Van Leuven, S. et al. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: A pooled analysis of the Rating Atherosclerotic Disease Change by Imaging With a New CETP Inhibitor (RADIANCE) trials. Circulation 2008, 118(24): 2515-2522
39. Kastelein, J.J., van Leuven, S.I., Burgess, L. et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007, 356(16): 1620-1630 (Pubitemid 46631671)
40. Barter, P.J., Caulfield, M., Eriksson, M. et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357(21): 2109-2122 (Pubitemid 350146106)
41. Forrest, M.J., Bloomfield, D., Briscoe, R.J. et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol 2008, 154(7): 1465-1473
42. Nissen, S., Tardif, J.C., Nicholls, S. et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007, 356(13): 1304-1316 (Pubitemid 46513296)
43. Barter, P.J., Brewer, H.B. Jr., Chapman, M.J., Hennekens, C.H., Rader, D.J., Tall, A.R. Cholesteryl ester transfer protein: A novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003, 23(2): 160-167
44. Grooth, G.J., Kuivenhoven, J.A., Stalenhoef, A.F. et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor JTT-705, in humans: A randomized phase II dose-response study. Circulation 2002, 105(18): 2159-2165
45. Kuivenhoven, J.A., de Grooth, G.J., Kawamura, H., Klerkx, A.H., Wilhelm, F., Trip, M.D., Kastelein, J.J. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am J Cardiol 2005, 95(9): 1085-1088 (Pubitemid 40544314)
46. Athyros, V.G., Mikhailidis, D.P., Kakafika, A.I. et al. Identifying and attaining LDL-C goals: Mission accomplished? Next target: New therapeutic options to raise HDL-C levels. Curr Drug Targets 2007, 8(3): 483-488
47. Komori, T. CETi-1. AVANT. Curr Opin Investig Drugs 2004, 5(3): 334-338
48. Ahmed, W., Orasanu, G., Nehra, V., Asatryan, L., Rader, D., Ziouzenkova, O., Plutzky, J. High-density lipoprotein hydrolysis by endothelial lipase activates PPAR α. Circulation Research 2006, 98(4): 490-498
49. Jin, W., Sun, G.S., Marchadier, D., Octtaviani, E., Glick, J.M., Rader, D.J. Endothelial cells secrete triglyceride lipase and phospholipase activities in responce to cytokines as a result of endothelial lipase. Circ Res. 2003, 92(6): 644-650 (Pubitemid 36417699)